Omigapil ameliorates the pathology of muscle dystrophy caused by laminin-α2 deficiency

Journal of Pharmacology and Experimental Therapeutics

Volumn 331, Issue 3, 2009, Pages 787-795

  Erb, Michael ^a   Meinen, Sarina ^b   Barzaghi, Patrizia ^a   Sumanovski, Lazar T ^a   Courdier Früh, Isabelle ^a   Rüegg, Markus A ^b   Meier, Thomas ^a  

^a Santhera Pharmaceuticals   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HISTONE ACETYLTRANSFERASE PCAF; LAMININ ALPHA2; MUSCLE RELAXANT AGENT; OMIGAPIL; PROTEIN P53; PROTEIN SIAH1; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; DIBENZO(B,F)OXEPIN 10 YLMETHYL METHYL PROP 2 YNYL AMINE; DIBENZO(B,F)OXEPIN-10-YLMETHYL-METHYL-PROP-2-YNYL-AMINE; LAMININ; NUCLEAR PROTEIN; OXEPINE DERIVATIVE; SEVEN IN ABSENTIA PROTEINS; UBIQUITIN PROTEIN LIGASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; GENE ACTIVATION; MOUSE; MUSCLE TISSUE; MUSCULAR DYSTROPHY; NONHUMAN; OVERALL SURVIVAL; PATHOLOGY; PRIORITY JOURNAL; PROTEIN DEFICIENCY; SKELETON MALFORMATION; ANIMAL; ANIMAL MUSCULAR DYSTROPHY; APOPTOSIS; BODY WEIGHT; ENZYMOLOGY; GENETICS; METABOLISM; MOTOR ACTIVITY; MOUSE MUTANT; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; SKELETAL MUSCLE;

ANIMALS; APOPTOSIS; BODY WEIGHT; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES; LAMININ; MICE; MICE, KNOCKOUT; MOTOR ACTIVITY; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, ANIMAL; NUCLEAR PROTEINS; OXEPINS; P300-CBP TRANSCRIPTION FACTORS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES;

EID: 73349085584     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.160754     Document Type: Article

References (37)

1. Andringa G, van Oosten RV, Unger W, Hafmans TG, Veening J, Stoof JC, and Cools AR (2000) Systemic administration of the propargylamine CGP 3466B prevents behavioural and morphological deficits in rats with 6-hydroxydopamine-induced lesions in the substantia nigra. Eur J Neurosci 12:3033-3043.
2. Bentzinger CF, Barzaghi P, Lin S, and Ruegg MA (2005) Overexpression of miniagrin in skeletal muscle increases muscle integrity and regenerative capacity in laminin-alpha2-deficient mice. FASEB J 19:934-942.
3. Briguet A, Courdier-Fruh I, Foster M, Meier T, and Magyar JP (2004) Histological parameters for the quantitative assessment of muscular dystrophy in the mdx-mouse. Neuromuscul Disord 14:675-682.
4. Carlile GW, Chalmers-Redman RM, Tatton NA, Pong A, Borden KE, and Tatton WG (2000) Reduced apoptosis after nerve growth factor and serum withdrawal: conversion of tetrameric glyceraldehyde-3-phosphate dehydrogenase to a dimer. Mol Pharmacol 57:2-12.
5. Chakravarti IM, Laha RG, and Roy J (1967) Handbook of Methods of Applied Statistics. John Wiley & Sons, Inc., New York.
6. Chuang DM, Hough C, and Senatorov VV (2005) Glyceraldehyde-3-phosphate dehydrogenase, apoptosis, and neurodegenerative diseases. Annu Rev Pharmacol Toxicol 45:269-290.
7. Colognato H and Yurchenco PD (2000) Form and function: the laminin family of heterotrimers. Dev Dyn 218:213-234.
8. Dastoor Z and Dreyer JL (2001) Potential role of nuclear translocation of glyceraldehyde-3-phosphate dehydrogenase in apoptosis and oxidative stress. J Cell Sci 114:1643-1653.
9. Dominov JA, Kravetz AJ, Ardelt M, Kostek CA, Beermann ML, and Miller JB (2005) Muscle-specific BCL2 expression ameliorates muscle disease in laminin α2-deficient, but not in dystrophin-deficient, mice. Hum Mol Genet 14:1029-1040.
10. Gawlik K, Miyagoe-Suzuki Y, Ekblom P, Takeda S, and Durbeej M (2004) Laminin α1 chain reduces muscular dystrophy in laminin α2 chain deficient mice. Hum Mol Genet 13:1775-1784.
11. Girgenrath M, Beermann ML, Vishnudas VK, Homma S, and Miller JB (2009) Pathology is alleviated by doxycycline in a laminin-alpha2-null model of congenital muscular dystrophy. Ann Neurol 65:47-56.
12. Girgenrath M, Dominov JA, Kostek CA, and Miller JB (2004) Inhibition of apoptosis improves outcome in a model of congenital muscular dystrophy. J Clin Invest 114:1635-1639.
13. Hara MR, Agrawal N, Kim SF, Cascio MB, Fujimuro M, Ozeki Y, Takahashi M, Cheah JH, Tankou SK, Hester LD, et al. (2005) S-Nitrosylated GAPDH initiates apoptotic cell death by nuclear translocation following Siah1 binding. Nat Cell Biol 7:665-674.
14. Hara MR, Thomas B, Cascio MB, Bae BI, Hester LD, Dawson VL, Dawson TM, Sawa A, and Snyder SH (2006) Neuroprotection by pharmacologic blockade of the GAPDH death cascade. Proc Natl Acad Sci U S A 103:3887-3889.
15. Hayashi YK, Tezak Z, Momoi T, Nonaka I, Garcia CA, Hoffman EP, and Arahata K (2001) Massive muscle cell degeneration in the early stage of merosin-deficient congenital muscular dystrophy. Neuromuscul Disord 11:350-359.
16. Kragten E, Lalande I, Zimmermann K, Roggo S, Schindler P, Muller D, van Oostrum J, Waldmeier P, and Furst P (1998) Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(-)-deprenyl. J Biol Chem 273:5821-5828.
17. Kuang W, Xu H, Vachon PH, Liu L, Loechel F, Wewer UM, and Engvall E (1998) Merosin-deficient congenital muscular dystrophy. Partial genetic correction in two mouse models. J Clin Invest 102:844-852.
18. Kuang W, Xu H, Vilquin JT, and Engvall E (1999) Activation of the lama2 gene in muscle regeneration: abortive regeneration in laminin alpha2-deficiency. Lab Invest 79:1601-1613.
19. Langenbach KJ and Rando TA (2002) Inhibition of dystroglycan binding to laminin disrupts the PI3K/AKT pathway and survival signaling in muscle cells. Muscle Nerve 26:644-653.
20. Laprise P, Vallée K, Demers MJ, Bouchard V, Poirier EM, Vézina A, Reed JC, Rivard N, and Vachon PH (2003) Merosin (laminin-2/4)-driven survival signaling: complex modulations of Bcl-2 homologs. J Cell Biochem 89:1115-1125.
21. Meinen S, Barzaghi P, Lin S, Lochmüller H, and Ruegg MA (2007) Linker molecules between laminins and dystroglycan ameliorate laminin-alpha2-deficient muscular dystrophy at all disease stages. J Cell Biol 176:979-993.
22. Millay DP, Sargent MA, Osinska H, Baines CP, Barton ER, Vuagniaux G, Sweeney HL, Robbins J and Molkentin JD (2008) Genetic and pharmacologic inhibition of mitochondrial-dependent necrosis attenuates muscular dystrophy. Nat Med 14: 442-447.
23. Miller R, Bradley W, Cudkowicz M, Hubble J, Meininger V, Mitsumoto H, Moore D, Pohlmann H, Sauer D, Silani V, et al. (2007) Phase II/III randomized trial of TCH346 in patients with ALS. Neurology 69:776-784.
24. Miyagoe Y, Hanaoka K, Nonaka I, Hayasaka M, Nabeshima Y, Arahata K, Nabeshima Y, and Takeda S (1997) Laminin alpha2 chain-null mutant mice by targeted disruption of the Lama2 gene: a new model of merosin (laminin 2)-deficient congenital muscular dystrophy. FEBS Lett 415:33-39.
25. Moll J, Barzaghi P, Lin S, Bezakova G, Lochmüller H, Engvall E, Müller U, and Ruegg MA (2001) An agrin minigene rescues dystrophic symptoms in a mouse model for congenital muscular dystrophy. Nature 413:302-307.
26. Muntoni F and Voit T (2004) The congenital muscular dystrophies in 2004: a century of exciting progress. Neuromuscul Disord 14:635-649.
27. Olanow CW, Schapira AH, LeWitt PA, Kieburtz K, Sauer D, Olivieri G, Pohlmann H, and Hubble J (2006) TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 5:1013-1020.
28. Palma E, Tiepolo T, Angelin A, Sabatelli P, Maraldi NM, Basso E, Forte MA, Bernardi P, and Bonaldo P (2009) Genetic ablation of cyclophilin D rescues mitochondrial defects and prevents muscle apoptosis in collagen VI myopathic mice. Hum Mol Genet 18:2024-2031.
29. Qiao C, Li J, Zhu T, Draviam R, Watkins S, Ye X, Chen C, Li J, and Xiao X (2005) Amelioration of laminin-alpha2-deficient congenital muscular dystrophy by somatic gene transfer of miniagrin. Proc Natl Acad Sci U S A 102:11999-12004.
30. Sagot Y, Toni N, Perrelet D, Lurot S, King B, Rixner H, Mattenberger L, Waldmeier PC, and Kato AC (2000) An orally active anti-apoptotic molecule (CGP 3466B) preserves mitochondria and enhances survival in an animal model of motoneuron disease. Br J Pharmacol 131:721-728.
31. Schessl J, Zou Y, and Bönnemann CG (2006) Congenital muscular dystrophies and the extracellular matrix. Semin Pediatr Neurol 13:80-89.
32. Sen N, Hara MR, Ahmad AS, Cascio MB, Kamiya A, Ehmsen JT, Aggrawal N, Hester L, Doré S, Snyder SH, et al. (2009) GOSPEL: a neuroprotective protein that binds to GAPDH upon S-nitrosylation. Neuron 63:81-91.
33. Sen N, Hara MR, Kornberg MD, Cascio MB, Bae BI, Shahani N, Thomas B, Dawson TM, Dawson VL, Snyder SH, et al. (2008) Nitric oxide-induced nuclear GAPDH activates p300/CBP and mediates apoptosis. Nat Cell Biol 10:866-873.
34. Tarze A, Deniaud A, Le Bras M, Maillier E, Molle D, Larochette N, Zamzami N, Jan G, Kroemer G, and Brenner C (2007) GAPDH, a novel regulator of the proapoptotic mitochondrial membrane permeabilization. Oncogene 26:2606-2620.
35. Tatton W, Chalmers-Redman R, and Tatton N (2003) Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B. J Neural Transm 110:509-515.
36. Waldmeier P, Bozyczko-Coyne D, Williams M, and Vaught JL (2006) Recent clinical failures in Parkinson's disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases. Biochem Pharmacol 72:1197-1206.
37. Waldmeier PC, Boulton AA, Cools AR, Kato AC, and Tatton WG (2000) Neurorescuing effects of the GAPDH ligand CGP 3466B. J Neural Transm Suppl 2000: 197-214.